The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 5, 2011, Pages 637-646

  Hornby, Pamela J ^a   Moore, Beverley A ^b  

^a Cell Biology and Assay Technologies   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

diabetes; enteric nervous system; inflammatory bowel disease; mucositis; post operative ileus; short bowel syndrome; vagus nerve

Indexed keywords

ALVIMOPAN; ANTINEOPLASTIC AGENT; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; GASTRIC INHIBITORY POLYPEPTIDE; GATTEX; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 AGONIST; GLUCOSE; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 5; GROWTH HORMONE; HUMAN GROWTH HORMONE; IMMUNOGLOBULIN; INCRETIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PALIFERMIN; PLACEBO; PROSTAGLANDIN; SEROTONIN; SODIUM GLUCOSE COTRANSPORTER 1; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TEDUGLUTIDE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ABSORPTION; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE PANCREATITIS; APOPTOSIS; BLOOD LEVEL; CACHEXIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CARCINOGENESIS; CELL DAMAGE; CELL PROLIFERATION; CELL PROTECTION; CHEMOTHERAPY; COLITIS; COMPARATIVE STUDY; CROHN DISEASE; CRYPT CELL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; ENTERIC FEEDING; ENTERITIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MUCOSITIS; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HOSPITALIZATION; HUMAN; ILEUS; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE CANCER; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; LENGTH OF STAY; LONG TERM CARE; MALNUTRITION; MESENTERY BLOOD FLOW; METABOLIC SYNDROME X; MICROBIOME; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NECROTIZING ENTEROCOLITIS; NEWBORN DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL STATUS; PARENTERAL NUTRITION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; POSTOPERATIVE ILEUS; PROGNOSIS; QUALITY OF LIFE; RADIATION INJURY; RADIOTHERAPY; REVIEW; ROUX Y ANASTOMOSIS; SECRETION; SHORT BOWEL SYNDROME; STOMACH MUCOSA BLOOD FLOW; STOMATITIS; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; TREATMENT INDICATION; UTERINE CERVIX CANCER; WOUND HEALING;

ANIMALS; GASTROINTESTINAL DISEASES; GLUCAGON-LIKE PEPTIDE 2; HUMANS; ILEUS; INFLAMMATORY BOWEL DISEASES; MUCOSITIS; RECEPTORS, GLUCAGON; SHORT BOWEL SYNDROME;

EID: 79954470583     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.556620     Document Type: Review

References (90)

1. Sherwood NM, Krueckl SL, McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 2000;21:619-70 (Pubitemid 32113287)
2. Holst JJ. Glucagon and glucagon-like peptides 1 and 2. Results Probl Cell Differ 2010;50:121-35
3. Yusta B, Boushey RP, Drucker DJ. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem 2000;275:35345-52
4. Burrin DG, Stoll B, Guan X. Glucagon-like peptide 2 function in domestic animals. Domest Anim Endocrinol 2003;24:103-22 (Pubitemid 36238323)
5. Ichimura A, Hirasawa A, Hara T, et al. Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis. Prostaglandins Other Lipid Mediat 2009;89:82-8
6. Dube PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007;293:E460-5 (Pubitemid 47205088)
7. Wallis K, Walters JR, Forbes A. Review article: glucagon-like peptide 2-current applications and future directions. Aliment Pharmacol Ther 2007;25:365-72 (Pubitemid 46184449)
8. Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000;119:744-55
9. Orskov C, Hartmann B, Poulsen SS, et al. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005;124:105-12 (Pubitemid 39488347)
10. Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 2001;98:12497-502 (Pubitemid 33019974)
11. Amato A, Rotondo A, Cinci L, et al. Role of Cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon. Am J Physiol Gastrointest Liver Physiol 2010;299:G1038-44
12. Nelson DW, Sharp JW, Brownfield MS, et al. Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. Endocrinology 2007;148:1954-62 (Pubitemid 46997024)
13. Yusta B, Somwar R, Wang F, et al. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J Biol Chem 1999;274:30459-67
14. Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999;96:1569-73 (Pubitemid 29098492)
15. Lovshin J, Estall J, Yusta B, et al. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 2001;276:21489-99
16. Bulut K, Pennartz C, Felderbauer P, et al. Glucagon like peptide-2 induces intestinal restitution through VEGF release from subepithelial myofibroblasts. Eur J Pharmacol 2008;578:279-85
17. Estall JL, Drucker DJ. Glucagon-like peptide-2. Annu Rev Nutr 2006;26:391-411
18. Stephens J, Stoll B, Cottrell J, et al. Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets. Am J Physiol Regul Integr Comp Physiol 2006;290:R283-9
19. Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006;130:150-64 (Pubitemid 43049845)
20. Wojdemann M, Wettergren A, Hartmann B, et al. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33:828-32 (Pubitemid 28423636)
21. Nagell CF, Wettergren A, Pedersen JF, et al. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 2004;39:353-8 (Pubitemid 38526723)
22. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002;122:531-44 (Pubitemid 34117003)
23. Jeppesen PB. Glucagon-like peptide-2: update of the recent clinical trials. Gastroenterology 2006;130(2 Suppl 1):S127-31 (Pubitemid 43208870)
24. O'Brien DP, Nelson LA, Huang FS, et al. Intestinal adaptation: structure, function, and regulation. Semin Pediatr Surg 2001;10:56-64 (Pubitemid 32422653)
25. McMellen ME, Wakeman D, Longshore SW, et al. Growth factors: possible roles for clinical management of the short bowel syndrome. Semin Pediatr Surg 2010;19:35-43
26. Ohneda K, Ulshen MH, Fuller CR, et al. Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I. Gastroenterology 1997;112:444-54 (Pubitemid 27078831)
27. Geske MJ, Zhang X, Patel KK, et al. Fgf9 signaling regulates small intestinal elongation and mesenchymal development. Development 2008;135:2959-68
28. Sigalet DL, Martin GR, Butzner JD, et al. A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome. J Pediatr Surg 2005;40:763-8 (Pubitemid 40724843)
29. Housley RM, Morris CF, Boyle W, et al. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest 1994;94:1764-77 (Pubitemid 24348211)
30. Mardini HE, de Villiers WJ. Teduglutide in intestinal adaptation and repair: light at the end of the tunnel. Expert Opin Investig Drugs 2008;17:945-51 (Pubitemid 351864331)
31. Wallis K, Walters JR, Gabe S. Short bowel syndrome: the role of GLP-2 on improving outcome. Curr Opin Clin Nutr Metab Care 2009;12:526-32
32. Sigalet DL, Lam V, Boctor D. The assessment, and glucagon-like peptide-2 modulation, of intestinal absorption and function. Semin Pediatr Surg 2010;19:44-9
33. Bremholm L, Hornum M, Henriksen BM, et al. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 2009;44:314-19
34. Marier JF, Mouksassi MS, Gosselin NH, et al. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. J Clin Pharmacol 2010;50:36-49
35. NPS Pharmaceuticals Announces Completion of Treatment Phase in STEPS Registration Study of GATTEX in Short Bowel Syndrome. Bedminster, NJ: NPS press release 10 January 2011. Available from: http://www.npspcom/PressReleases/ 1514419 [Last Accessed 31 January 2011]
36. Sigalet DL, Martin G, Meddings J, et al. GLP-2 levels in infants with intestinal dysfunction. Pediatr Res 2004;56:371-6 (Pubitemid 39128821)
37. Sangild PT, Siggers RH, Schmidt M, et al. Diet-and colonization-dependent intestinal dysfunction predisposes to necrotizing enterocolitis in preterm pigs. Gastroenterology 2006;130:1776-92 (Pubitemid 43668865)
38. Mouksassi MS, Marier JF, Cyran J, et al. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther 2009;86:667-71
39. Taqi E, Wallace LE, de Heuvel E, et al. The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. J Pediatr Surg 2010;45:987-95
40. Garrison AP, Dekaney CM, von Allmen DC, et al. Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion. Am J Physiol Gastrointest Liver Physiol 2009;296:G643-50
41. Kaji T, Tanaka H, Redstone H, et al. Temporal changes in the intestinal growth promoting effects of glucagon-like peptide 2 following intestinal resection. J Surg Res 2009;152:271-80
42. Wallace LE, Sharkey KA, Sigalet D. GLP-2 Treatment protects against neuronal loss and enhances the expression of VIP in the Submucosal Plexus in TNBS Colitis. Gastroenterology 2008;134(Suppl 1):A-542, abstract T1378
43. Sigalet DL, Wallace LE, Holst JJ, et al. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007;293:G211-21 (Pubitemid 47105173)
44. Lomax AE, O'Hara JR, Hyland NP, et al. Persistent alterations to enteric neural signaling in the guinea pig colon following the resolution of colitis. Am J Physiol Gastrointest Liver Physiol 2007;292:G482-91
45. O'Hara JR, Lomax AE, Mawe GM, et al. Ileitis alters neuronal and enteroendocrine signalling in guinea pig distal colon. Gut 2007;56:186-94
46. Arthur GL, Schwartz MZ, Kuenzler KA, et al. Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. J Pediatr Surg 2004;39:448-52; discussion 452 (Pubitemid 38338365)
47. Drucker DJ, Yusta B, Boushey RP, et al. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999;276:G79-91 (Pubitemid 29063603)
48. L'Heureux MC, Brubaker PL. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther 2003;306:347-54 (Pubitemid 36734391)
49. Buchman AL, Katz S, Fang JC, et al. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 2010;16:962-73
50. Yazbeck R, Howarth GS, Abbott CA. Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward? Cytokine Growth Factor Rev 2009;20:175-84
51. Schnabel CA, Wintle M, Kolterman O. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag 2006;2:69-77
52. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40 (Pubitemid 41060966)
53. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988;123:2009-13
54. de Heer J, Pedersen J, Orskov C, et al. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 2007;50:2135-42 (Pubitemid 47373847)
55. Bahrami J, Longuet C, Baggio LL, et al. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology 2010;139:857-68
56. Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006;130:44-54 (Pubitemid 43049834)
57. Sorensen LB, Flint A, Raben A, et al. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 2003;27:450-66
58. Christensen M, Knop FK, Vilsboll T, et al. Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regul Pept 2010;163:96-101
59. Cameron HL, Perdue MH. Stress impairs murine intestinal barrier function: improvement by glucagon-like peptide-2. J Pharmacol Exp Ther 2005;314:214-20 (Pubitemid 41058258)
60. Cameron HL, Yang PC, Perdue MH. Glucagon-like peptide-2-enhanced barrier function reduces pathophysiology in a model of food allergy. Am J Physiol Gastrointest Liver Physiol 2003;284:G905-12 (Pubitemid 36597332)
61. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-103
62. Moore BA, Peffer N, Pirone A, et al. GLP-2 receptor agonism ameliorates inflammation and gastrointestinal stasis in murine postoperative ileus. J Pharmacol Exp Ther 2010;333:574-83
63. Watson AJ, Duckworth CA. Gut microbiota control gut permeability through GLP-2. Gastroenterology 2010;138:779-81
64. Kouris GJ, Liu Q, Rossi H, et al. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Am J Surg 2001;181:571-5 (Pubitemid 32769988)
65. Fukuda H, Suenaga K, Tsuchida D, et al. The selective mu opioid receptor antagonist, alvimopan, improves delayed GI transit of postoperative ileus in rats. Brain Res 2006;1102:63-70 (Pubitemid 44092657)
66. Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg 2000;87:1480-93
67. van der Spoel JI, Oudemans-van Straaten HM, Stoutenbeek CP, et al. Neostigmine resolves critical illness-related colonic ileus in intensive care patients with multiple organ failure-a prospective, double-blind, placebo-controlled trial. Intensive Care Med 2001;27:822-7 (Pubitemid 32480509)
68. Bauer AJ, Schwarz NT, Moore BA, et al. Ileus in critical illness: mechanisms and management. Curr Opin Crit Care 2002;8:152-7 (Pubitemid 36132686)
69. Moore BA, Otterbein LE, Turler A, et al. Inhaled carbon monoxide suppresses the development of postoperative ileus in the murine small intestine. Gastroenterology 2003;124:377-91 (Pubitemid 36169255)
70. Shibata C, Naito H, Jin XL, et al. Effect of glucagon, glicentin, glucagon-like peptide-1 and-2 on interdigestive gastroduodenal motility in dogs with a vagally denervated gastric pouch. Scand J Gastroenterol 2001;36:1049-55 (Pubitemid 32801689)
71. van der Zanden EP, Snoek SA, Heinsbroek SE, et al. Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor alpha4beta2. Gastroenterology 2009;137(3):1029-39, 39 e1-4
72. Schwarz NT, Beer-Stolz D, Simmons RL, et al. Pathogenesis of paralytic ileus: intestinal manipulation opens a transient pathway between the intestinal lumen and the leukocytic infiltrate of the jejunal muscularis. Ann Surg 2002;235:31-40 (Pubitemid 34062397)
73. Turler A, Schnurr C, Nakao A, et al. Endogenous endotoxin participates in causing a panenteric inflammatory ileus after colonic surgery. Ann Surg 2007;245:734-44 (Pubitemid 46684103)
74. Balda MS, Whitney JA, Flores C, et al. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J Cell Biol 1996;134:1031-49 (Pubitemid 26278226)
75. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100(Suppl 9):1995-2025 (Pubitemid 38528741)
76. Rapoport AP, Miller Watelet LF, Linder T, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999;17:2446-53 (Pubitemid 29368244)
77. Langer CJ, Hoffman JP, Ottery FD. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition 2001;17(Suppl 1):S1-20
78. Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997;90:3204-13 (Pubitemid 27444217)
79. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-9 (Pubitemid 30235880)
80. Yazbeck R, Abbott CA, Howarth GS. The use of GLP-2 and related growth factors in intestinal diseases. Curr Opin Investig Drugs 2010;11:440-6
81. Moon Y, Yang H, Kim YB. Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells. Toxicol Appl Pharmacol 2007;223:155-63 (Pubitemid 47348058)
82. Elting LS, Cantor SB, Martin CG, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 2003;97:1541-50 (Pubitemid 36297784)
83. Enestvedt CK, Thompson SK, Chang EY, et al. Clinical review: healing in gastrointestinal anastomoses, part II. Microsurgery 2006;26:137-43
84. Wheeless CR Jr, Zanagnolo V, Bowers D, et al. The effect of growth hormone on the bursting strength of ileal anastomotic segments in radiation-injured rat bowel. Gynecol Oncol 1998;70:121-2 (Pubitemid 28368888)
85. Zacharakis E, Demetriades H, Kanellos DS, et al. Contribution of insulin-like growth factor I to the healing of colonic anastomoses in rats. J Invest Surg 2007;20:9-14 (Pubitemid 46957604)
86. Redstone RA, Buie WD, Hart DA, et al. The effect of glucagon-like peptide-2 receptor agonists on colonic anastomotic wound healing. Gastroenterol Res Pract 2010. [Epub ahead of print]
87. Koehler JA, Harper W, Barnard M, et al. Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res 2008;68:7897-904
88. Iakoubov R, Lauffer LM, Trivedi S, et al. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology 2009;150:4033-43
89. Koehler JA, Yusta B, Drucker DJ. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol 2005;19:459-73 (Pubitemid 40223469)
90. Ivory CP, Wallace LE, McCafferty DM, et al. Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2008;295:G1202-10